DIPG

MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Children, Biotechnology, Health, Pharmaceutical, Oncology, Research, Family, Hospitals, Consumer, Science, Clinical Trials, Cancer, Central nervous system, Radiation, Immune system, MAIA, Ohio State University, Cell proliferation, Nationwide Children's Hospital, Nationwide, Hospital, Brain, AACR, Survival rate, Prognosis, CNS, Associate, Survival, Immunotherapy, DIPG

The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.

Key Points: 
  • The research was conducted in collaboration with Nationwide Children's Hospital and led by Dr. Drissi.
  • The study explored the combination of THIO and ionizing radiation (IR) treatments to induce direct anticancer effects and stimulate anti-tumor immunity in diffuse intrinsic pontine glioma (DIPG).
  • DIPG, a very difficult-to-treat and high-risk childhood cancer, is a central nervous system (CNS) tumor that forms in the brainstem.
  • Scientists from Nationwide Children’s Hospital and MAIA have shown that THIO synergistically sensitizes DIPG cells to ionizing radiation (IR), significantly decreasing cell proliferation.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024
Brain, Type 2, LMD, Legislation, Incidence, C-peptide, Cancer, SNY, Panobinostat, GBM, Letter, Trial of the century, Neoplasm, CFO, Diffusion, Cell proliferation, Central nervous system, Apoptosis, Type 1 diabetes, Patent, Breast, Metabolism, Diffuse intrinsic pontine glioma, Type 2 diabetes, Survival, DIPG, MGMT, Patient, Toxicology, Glioblastoma, Tolimidone, Pfizer, Insulin, OXPHOS, Plasma, Oxidative phosphorylation, FDA, Progression-free survival, Convection, Columbia University, Type 1, Cerebrospinal fluid, DMG, Pharmaceutical industry

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Retrieved on: 
Wednesday, January 17, 2024
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, University, Neoplasm, Lantern, Patient, Therapy, Research, Neurology, Glioblastoma, UC, Multimedia, Neuro, Brain, DIPG, Cancer, NCI, Starlight, ATRT, USC, Central nervous system, Seagen, Physician, CNS, Pharmaceutical industry

Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D.

Key Points: 
  • Starlight Therapeutics— a Lantern Pharma (Nasdaq: LTRN) subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options— today announced that Marc Chamberlain, M.D.
  • has joined Starlight as its Chief Medical Officer.
  • In his role, Dr. Chamberlain will apply his significant medical, clinical, and pharmaceutical development expertise to advance Starlight’s AI-enabled and accelerated drug development portfolio.
  • “Starlight, in collaboration with Lantern Pharma, is poised to advance its novel central nervous system (CNS) penetrant wholly synthetic acylfulvene, LP-184 (referred to as “STAR-001” for CNS indications), to target tumors in the brain.

Slalom Collaborates with AWS and DIPG DMG Research Funding Alliance to Fight Childhood Brain Cancer with Data

Retrieved on: 
Thursday, December 14, 2023
Neoplasm, AWS, Diffusion, Caregiver, Mevalonate pathway, DMG, Research, Slalom, Parent, Disease, Cancer, Life expectancy, Brain, Death, Diffuse intrinsic pontine glioma, Ward, Child, DIPG, Central nervous system, Diagnosis, Amazon Web Services, Pharmaceutical industry

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to create the DIPG One Link , a unique centralized resource hub that helps accelerate research and awareness of Diffuse Intrinsic Pontine Glioma (DIPG), also known as Diffuse Midline Glioma (DMG).

Key Points: 
  • SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to create the DIPG One Link , a unique centralized resource hub that helps accelerate research and awareness of Diffuse Intrinsic Pontine Glioma (DIPG), also known as Diffuse Midline Glioma (DMG).
  • DIPG DMG is a rare and often fatal form of childhood brain cancer with limited treatment options and scarce research data.
  • “As parents fighting DIPG alongside our children we discovered significant gaps in the system which expects parents to navigate their child’s care.
  • With AWS, Slalom executed the research, design, and development of the DIPG One Link website to support those looking for information to fight DIPG DMG.

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Parkinson's disease, Pancreatic cancer, Glioma, Mesothelioma, OTCQB, Security (finance), Therapy, CFO, Disease, Patient, Artificial intelligence, PDAC, G&A, COVID-19, JV, Growth, DIPG, WalletHub, Pharmaceutical industry, Hong Kong

AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).

Key Points: 
  • AGOURA HILLS, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).
  • The financial results are based on the Quarterly Report on Form 10-Q as filed with the Securities and Exchange Commission on November 14, 2023.
  • Highlights for Q3 2023 and thereafter:
    We have been enjoying the effects of the benefits of the JV transaction, between Dragon Overseas Limited (“Dragon”) and us, through the formation of GMP Biotechnology Limited (“GMP Bio” or “JV”) being reflected in our financial results.
  • “Commencing April 2022, with the culmination of the JV with Dragon, and continuing into 2023 till date, have been a good eighteen months for us.

SonALAsense Presents Preliminary Data From Clinical Study in Patients With Deadly Pediatric Brain Tumor

Retrieved on: 
Wednesday, December 13, 2023
Surgery, Medical Devices, Neurology, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, SDT, Radiation, Hope, Pakistan Society of Neuro-Oncology, Sonodynamic therapy, Patient, Aminolevulinic acid, Death, Diffusion, Steroid, Incisionless Fritsch otoplasty, Neurosurgery, Hydrogen chloride, Diagnosis, Survival, Diffuse intrinsic pontine glioma, Infrared spectroscopy correlation table, Quality of life, DIPG, SNO, Metastasis, Medical imaging, Pharmaceutical industry, Development

These results were presented at the November 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.

Key Points: 
  • These results were presented at the November 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.
  • The preliminary data from Study SDT-201 shows signals of clinical activity and no safety concerns.
  • Study SDT-201 is a dose escalation and expansion study in patients with DIPG.
  • Six (6) patients have been treated to date and dose escalation is ongoing.

Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors

Retrieved on: 
Tuesday, December 5, 2023
Other Health, Research, Pharmaceutical, Oncology, Consumer, Hospitals, Children, Clinical Trials, Science, Biotechnology, Other Science, Health, CNS, Juno Therapeutics, Seattle Children's, Bristol Myers Squibb, Safety, Brainchild, Therapy, Glioblastoma, Brain, Leukemia, Patient, Multimedia, GSK, Neoplasm, Child, Diffuse intrinsic pontine glioma, Cancer, R, Transgene, Immunotherapy, Lymphoma, Central nervous system, Pharmaceutical industry, DIPG

Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.

Key Points: 
  • Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.
  • BrainChild Bio will be granted an exclusive license to novel CAR T-cell technology for CNS tumors developed at Seattle Children’s and will build upon the pioneering CAR T-cell therapy and clinical translational work of Michael Jensen, M.D., and his team at Seattle Children’s Therapeutics.
  • Seattle Children’s has provided the initial equity funding for BrainChild Bio which will operate as an independently managed corporation.
  • The launch of BrainChild Bio is a natural progression of Seattle Children’s Therapeutics’ goal to expand access to potentially life-changing therapies through collaborations with biotech companies.

FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, FDA, Medical Devices, Neurology, Clinical Trials, Biotechnology, Brain, SDT, Safety, Annual general meeting, Radiation, ALA, Pons, Pakistan Society of Neuro-Oncology, Plasma protein binding, Collection, Sonodynamic therapy, Patient, Heart rate, Light, NCT, Hydrogen chloride, Diffuse intrinsic pontine glioma, Survival, Diagnosis, Trial of the century, Communication, Biomarker, DIPG, SNO, Spinal cord, Blood pressure, Pharmaceutical industry, Development

This builds upon SONALA-001 also having received orphan drug designation in 2021 for malignant gliomas.

Key Points: 
  • This builds upon SONALA-001 also having received orphan drug designation in 2021 for malignant gliomas.
  • The FDA’s Fast Track is a process designed to facilitate the development, and expedited review, of drugs to treat serious conditions and fill an unmet medical need.
  • “Receiving Fast Track Designation underscores the immediate and urgent need to bring new therapy options for DIPG patients,” said Ely Benaim, M.D., SonALAsense’s Chief Medical Officer and Executive Vice President of Development.
  • Approximately 300 children are diagnosed with DIPG each year in the US, usually between the ages of 5 and 9.

EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG

Retrieved on: 
Tuesday, November 14, 2023
Science, Neurology, Research, Oncology, Health, FDA, Medical Devices, Clinical Trials, CNS, Safety, Education, Therapy, Treatment, Ageing, HDE, Glioblastoma, Disease, GBM, Brain, Diffusion, Neuro-Oncology (journal), A1A, Neoplasm, Diagnosis, Survival, Emulate, Radio, DIPG, Society, SNO, Poster, Medical imaging

The accepted abstract will be published in SNO’s official journal, Neuro-Oncology, which is now available at https://academic.oup.com/neuro-oncology/supplements .

Key Points: 
  • The accepted abstract will be published in SNO’s official journal, Neuro-Oncology, which is now available at https://academic.oup.com/neuro-oncology/supplements .
  • The abstract describes the poster material developed by EMTx for the SNO meeting and can be downloaded from EMTx’s website for viewing here .
  • DIPG makes up 10-15% of all brain tumors in children, with about 150-300 new diagnoses per year in the United States.
  • EMTx is dedicated to changing the treatment and prolonging survival in both DIPG and GBM.

Pioneer Launches Venture Group to Fund the Fight Against Rare Pediatric Brain Cancer

Retrieved on: 
Wednesday, December 6, 2023
Arm, Attention, Koenen, Research, CD200, Radiation, Immune system, Therapy, Pediatrics, University, Glioblastoma, Diffuse intrinsic pontine glioma, OX2, FDA, Child, Peter Westerhaus, MD, Diagnosis, Pioneer, Doctor of Philosophy, Immunotherapy, DIPG, Children's Hospital, Mutation, Cell, Life, Hospital, Pharmaceutical industry, Birth control, Charles Moertel

"We've been working to start a venture arm for more than five years now," said Pioneer founder and co-owner, Brian Westerhaus.

Key Points: 
  • "We've been working to start a venture arm for more than five years now," said Pioneer founder and co-owner, Brian Westerhaus.
  • (Koenen is a partner and co-owner at Pioneer Management Consulting and Pioneer Ventures Group.)
  • It gets less than 4% of all cancer research dollars available, and almost none of that goes to rare types, like DIPG.
  • To donate to the pediatric trial at Children's Hospital in Minnesota, please contact Teri Cannon [email protected]